• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Amgen Posts Q4 Loss, Misses Street

Quote

Mark Benson

new user
$AMGN Amgen reported a loss in the fourth quarter of 2017 due to the inclusion of a $6.1 billion charge related to the impacts of the U.S. corporate tax reform. The results came in below analysts expectations. In addition, the company issued guidance for the year 2018, which remained in line with consensus estimate.

A tablet form of the results can be found at http://alph.st/ba48b1a2
 














Amgen early oncology commercial Sanket Agarwal likes Bluebird so it must be a winner!

Disclosure: Sanket has no prior Pharma marketing, field sales or even a strong R&D background in life sciences. He touts his online MPH like he has a Ph.D and studied oncology mechanisms for the last 2 decades. Real winner leading Amgen oncology!
 




anonymous said:
Amgen early oncology commercial Sanket Agarwal likes Bluebird so it must be a winner!

Disclosure: Sanket has no prior Pharma marketing, field sales or even a strong R&D background in life sciences. He touts his online MPH like he has a Ph.D and studied oncology mechanisms for the last 2 decades. Real winner leading Amgen oncology!
Click to expand...


I've interacted with this guy. He does nothing. Knows nothing. I can't believe he gets promoted despite his incompetence.
 




anonymous said:
I've interacted with this guy. He does nothing. Knows nothing. I can't believe he gets promoted despite his incompetence.
Click to expand...

Agree that he does not know much but he's duped others into believing he is a visionary. He focuses his time and effort on managing relationships with people above him. That is how he has unlocked the key to his promotions.
 




anonymous said:
Agree that he does not know much but he's duped others into believing he is a visionary. He focuses his time and effort on managing relationships with people above him. That is how he has unlocked the key to his promotions.
Click to expand...

I’ve been in groups and meetings with him and he has absolutely no substance and is no visionary by any means. How can he be a visionary without understand the basics of oncology or science. You are right in the fact that he does a great job of managing relationships of those above him. People know that he has great relationships with senior management so they are reluctant to say bad things about him or give a true assessment of his lack of performance for fear of repercussions. How can you build a leading oncology pipeline that with compete with the Genentech’s, Celgene, BMS, Merck of the world, let alone Pfizer, Astrazenca, Takeda and JnJ.

Amgen keeps touting its oncology but if you remove the support case products the current drugs and pipeline is thin compared to other pharmas.
 








anonymous said:
Most leaders are relationship builders not visionaries or even super smart. Name the exception. I'll check back after a few weeks.
Click to expand...

I agree they understand who they need to write a good 360 review and do they things to make themselves likable for those favorable reviews. It’s about playing the game. Talent , hard work, not needed.

Sanket is no exception.
 




anonymous said:
I’ve been in groups and meetings with him and he has absolutely no substance and is no visionary by any means. How can he be a visionary without understand the basics of oncology or science. You are right in the fact that he does a great job of managing relationships of those above him. People know that he has great relationships with senior management so they are reluctant to say bad things about him or give a true assessment of his lack of performance for fear of repercussions. How can you build a leading oncology pipeline that with compete with the Genentech’s, Celgene, BMS, Merck of the world, let alone Pfizer, Astrazenca, Takeda and JnJ.

Amgen keeps touting its oncology but if you remove the support case products the current drugs and pipeline is thin compared to other pharmas.
Click to expand...
Look at the present and historical oncology pipeline. Amgen's internal oncology research shop has never produced a single successful cancer drug that wasn't supportive. Even Amgen Neuroscience, the laughing stock of the industry, has produced Aimovig! Time to wake up SH
 




anonymous said:
Look at the present and historical oncology pipeline. Amgen's internal oncology research shop has never produced a single successful cancer drug that wasn't supportive. Even Amgen Neuroscience, the laughing stock of the industry, has produced Aimovig! Time to wake up SH
Click to expand...

That’s true. Vectibix, blin, and Imlygic were all acquisitions (poor ones too - at least from commercial success )
 




















Top Bottom
Back
Quote